EYE 201
Alternative Names: EYE-201; MK-8748; TiespectusLatest Information Update: 02 Jan 2025
Price :
$50 *
At a glance
- Originator EyeBio
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Age-related macular degeneration; Diabetic macular oedema; Retinal vein occlusion
Most Recent Events
- 31 Oct 2024 Phase-I/II clinical trials in Age-related macular degeneration in USA (Intravitreous) (NCT06664502)
- 31 Oct 2024 Phase-I/II clinical trials in Diabetic macular oedema in USA (Intravitreous) (NCT06664502)
- 31 Oct 2024 Phase-I/II clinical trials in Retinal vein occlusion in USA (Intravitreous) (NCT06664502)